January 1st, 2016

James M. McKiernan MD

161 Fort Washington Ave New York New York 10032 JMM23@Columbia.edu


Personal data: James Michael McKiernan, M.D.

Born .9/18/67, Metuchen, NJ USA; US Citizen


Education

Johns Hopkins University B.A. Biology

1989

Columbia University College of Physicians & Surgeons

M.D.

1993



Postdoctoral Training:


Internship: Surgery

1993-1994

Department of Surgery

Columbia Presbyterian Medical Center New York, New York


Residency: Surgery

1994-1995

Department of Surgery

Columbia Presbyterian Medical Center New York, New York


Residency: Urology

1995-1999

Department of Urology

Columbia Presbyterian Medical Center New York, New York


Fellowship: Urologic Oncology

1999-2001

Department of Urology

Memorial Sloan-Kettering Cancer Center New York, New York


Licensure: New York State 1996 # 202833

Board qualification: Board certified American Board of Urology 2003

Recertified American Board of Urology 2012


Military Service: None

Professional organizations and societies:


1993 Alpha Omega Alpha Honor Society

1995 American Urologic Association

1997 American Association for Cancer Research

2001 New York Academy of Medicine

2001 American Society of Clinical Oncology

2001 Southwest Oncology Group

2003 American Medical Association

2004 Society of Urologic Oncology

2006- American Joint Committee on Cancer TNM Staging Commitee

2007-2012 New York Clinical Society

2008-2012 American Board of Urology Exam Committee 2011- New York Medical/Surgical Society


Academic appointments:


Postgraduate Urology Fellow Memorial Sloan Kettering Cancer Center 1999-2001 Assistant Professor of Urology Columbia University 2001-2007

John and Irene Given Foundation Chair in Urology 2007-11 Associate Professor of Urology Columbia University 2007-2010 Professor of Urology Columbia University 2010-

Director of Urologic Oncology Columbia University Department of Urology 2005- Vice Chairman Department of Urology 2006-2013

George F. Cahill Professor of Urology 2011-2014

Interim Chairman, Department of Urology Columbia University 2013-2014 John K. Lattimer Professor and Chairman, Department of Urology 2014-


Hospital appointments:


Postgraduate Residency Fellow Columbia Presbyterian Medical Center 1993-1999 Postgraduate Research Fellow Memorial Sloan Kettering Cancer Center 1999-2001 Assistant Attending Urologist New York Presbyterian Hospital 2001-2005 Associate Attending Urologist New York Presbyterian Hospital 2007-2009 Attending Urologist New York Presbyterian Hospital 2009-

Interim Urologist in Chief New York Presbyterian Hospital 2013-2014 Urologist-in Chief New York Presbyterian Hospital 2014-


Honors:


1989 Johns Hopkins University Dean’s List

1990-1993 Howard G. Lapsley Medical Student Scholarship Award 1993 Dr. Howard Lee Meierhof Memorial Prize in Pathology

1996 1st Prize NY Academy of Medicine Valentine Essay

1996 Columbia Presbyerian Medical Center Clinical Research Award 1997 3rd Prize NY Academy of Medicine Valentine Essay

1998 Columbia Presbyterian Medical Center Clinical Research Award 1998 International Society of Preventive Oncology Award

1999 Winner, NY Academy of Medicine Resident Debate Contest

1999 The Arnold P. Gold Foundation Resident Teaching Award

2002 American Cancer Society Pilot Award

2004 Department of Urology Teacher of the Year Award

2004 American Urologic Association Young Leadership Recipient

2011 James M. McKiernan, Prize for Compassionate Care: Awarded to graduating Columbia University College of P&S medical student

2012 Stephen Streem Memorial Award (SSMOLE) American Board of Urology Exam Committee

2013 Arnold P. Gold Foundation Humanism in Medicine Award 2013


Grant funding history:


Identification of amplified genes associated with germ cell tumor chemotherapy resistance by microarray comparative genomic hybridization and expression analyses. MSKCC Translational and integrative medicine research fund. 2001-2002 Principle Investigator $50,000


Role of hypermethylation and gene silencing in the development of chemotherapy resistance in male germ cell tumors. American cancer society pilot award 2002-2003 Principle Investigator $25,000


Facilitators & Barriers to Prostate Cancer Screening in Older African-American & African-Caribbean Men NIH U 54 grant 2002-2006 $15,000 annually.


Phase I trial of intravesical docetaxel for the treatment of BCG refractory urothelial cancer of the bladder. 2004-2006. $135,000.


Preclinical analyses of PTEN/P53 pathway in human bladder cancer.

Stewart Foundation for Cancer Research 2008-2009 Principle Investigator $50,000.


Aureon Biosystems Prostate Cancer Risk stratification in active surveillance clinical research grant 2010-2012 $50,000.


“Phase I/II clinical trial of intravesical nanoparticle encapsulated paclitaxel in the management of human BCG refractory bladder cancer” 2009-2013 Principle Investigator

$305,000.


Albert Einstein Translational Research training grant mentor 2010-2011

$16,000.

Prostate Cancer diagnostic biomarker discovery and validation Exosome diagnostics and Columbia University Biotechnology Partnership 2011-2012 Principle Investigator

$50,000.


Prostate Cancer diagnostic biomarker discovery and validation Prostate Cancer Foundation Grant 2012-2013 Principle Investigator $90,000.


Prostate Cancer diagnostic biomarker discovery and validation 2013-2014 Principle Investigator $90,000.


Cisplatin,gemcitabine, and cabazitaxel in the treatment of BCG refactory urothelial carcinoma of the bladder. 2013-2015 $184,000.


NIH Small Business Innovative Research (SBIR) Grant

Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for the treatment of BCG refractory urothelial carcinoma of the bladder.

Award Number R42CA171552. 2012-2015. $ 1,316,620


Ongoing IRB approved clinical trials:


Comprehensive Urologic oncology outcomes research protocol in prostate, kidney, and bladder cancer. Principle investigator 2001-2013


Phase I/II clinical trial of intravesical albumin bound paclitaxel in the treatement of BCG refractory high risk superficial bladder cancer. 2008-2013. Principle Investigator.


Delayed intervention versus surgery in small renal masses, a prospective registration trial. (Johns Hopkins University, Columbia University) 2009-


Dianostic and prognostic value of exosome associated mRNA in urologic oncology decision making. 2011- Principle Investigator


Cisplatin,gemcitabine, and cabazitaxel in the treatment of BCG refactory urothelial carcinoma of the bladder. 2013-


The role of FGF 23 in the prediction of acute and chronic renal damage following surgery for renal cortical malignancies. 2013-


Departmental and University committees:


1995-1999 Urology Resident Education Committee Columbia University

1999-2000 Clinical Care Pathways Committee Memorial Sloan- Kettering Cancer Center Department of Urology

1999-2001 Operating Room Committee Memorial Sloan-Kettering Cancer Center

2001-2010 Valentine essay competition director Columbia University

2002- Doris Duke Clinical Research Fellowship Faculty Mentor

2001- Dean’s Adviser for Urology residency match program

2001- Columbia P&S Club Faculty Advisory Board

2001-2005 Columbia P&S third year medical student lecturer

2003- Director 4th Year medical student Urology clerkship

2001-2005 Herbert Irving Cancer Center Protocol Review Committee

2003-2004 Vice Chariman Herbert Irving Cancer Center Protocol Review Committee

2004-2005 Chairman Herbert Irving Cancer Center Protocol Review Committee

2003- Columbia University College of Physicians and Surgeons Faculty Council

2004-2006 Columbia University College of Physicians and Surgeons Faculty Council Executive Committee

2004-2006 New York Presbyterian Hospital Operating Room Committee

2004-2012 Resident education committee Department of Urolgy CUMC

2006-2013 Department of Urology Executive Committee

2006-2008 Treasurer Presbyterian Hospital Alumni Society

2009-2010 Secretary New York Presbyterian Hospital Alumni Society

2008-2012 American Board of Urology/AUA Exam Committee Task Force C

2009-2012 Columbia Doctors Faculty Practice Organization Board of Governors

2010-2011 Dept of Opthalmology Chairman search committee

2010-2012 Columbia University Medical Center Society of Practitioners executive committee

2009-2012 Curriculum evaluation and research committee Columbia University College of Physicians and Surgeons

2010 Scientific Co-Chairman NY Section American Urologic Association Annual Meeting

2010-2011 President NY Presbyterian Hospital Alumni Society

2011-2012 Committee on advancement and promotions (COAP)

2012-2013 Chairman Clinical Faculty Academic Track Committee for the Health Sciences campus of Columbia University

2012- Chairman Academy of Master Clinicians at Columbia University Medical Center

2012 Urologic Consultant Columbia University Executive/International Consultation Service

2014- Faculty Practice Organization Finance Committee

2014- Herbert Irving Comprehensive Cancer Center Advisory Council

2015 Department of Radiation Oncology Chairman Search Committee


Teaching experience and responsibilities:


3rd Year Medical student clerkship lecturer in Urology 2001-2013 3rd Year Medical student clerkship director in Urology 2007-2013 4th Year Medical student Urology subinternship director 2001- Dean’s adviser for career counseling in Urology 2001-

Columbia University Clinical Faculty Committee 2009-2013


Teaching and mentorship:


Manlio Goetzel Doris Duke Research Fellow 2002-2003 Joel Decastro MD/MPH candidate 2003-2004

Alana Murphy Doris Duke Research Fellow 2003-2004 Robert Mitchell Research Study Coordinator 2004-2005 Puneet Masson Doris Duke Research Fellow 2004-2005 Ying Hua Doris Duke Research Fellow 2004-2005

Philip Pierazario Doris Duke Research Fellow 2005-2006 Tara McAnn Research Data Analyst 2005-2009

Meghan Spyres Research Study Coordniator 2005-2006 Mark Mann Doris Duke Research Fellow 2006-2007

Piruz Motemedinia Traslational Research Fellow 2006-2007 Melissa Laudano Doris Duke Research Fellow 2007-2008 Lamont Barlow Doris Duke Research Fellow 2008-2009 Catherine Seager Doris Duke Research Fellow 2008-2009 Matthew Wosnitzer MD Postdoctoral Research Fellow 2009-2010 Trushar Patel MD Postdoctoral Research Fellow 2009-2010

Max Kates Doris Duke Reseach Fellow 2010-2011 Olga Yeschina Doris Duke Research Fellow 2010-2011 Neda Sadeghi Clinical Research Fellow 2010-2011

Gina Badalato MD Postgraduate Research Fellow 2010-2011 Dara Holder Doris Duke Research Fellow 2011-2012 Michael Lipsky Doris Duke Research Fellow 2011-2012 Crytal V. Casteneda Doris Duke Research Fellow 2012-2013 Bailey Zampella Postdoctoral Research Fellow 2012-2013 Natasha Leigh Postdoctoral Research Fellow 2012-2013 Rashed Ghandour MD Postdoctoral Fellow 2013-2014 Mathew Danzig Clinical Research Fellow 2013-2014

Byron Dubow Clinical Research Fellow 2013-2014 Daniel Lascano Clinical Research Fellow 2014-2015 Jaime Pak Clinical Research Fellow 2014-2015 Wilson Sui Clinical Research Fellow 2015-2016

Ifeanyi Onyei Clinical Research Fellow 2015-2016 Maxwell James Clinical Research Fellow 2015-2016


Scientific journal editorial review boards:


Cancer Urology

Journal of Urology

Journal of Clinical Oncology Urological Research

Renal Medicine News

Urologic Oncology Seminars and Original Investigations American Journal of Urology Review

Clinical and Experimental Metastases British Journal of Urology International American Journal of Oncology Review Nanomedicine

European Oncology


Regional and National Committees:


AUA Young Urologists Committee 2004-2010

American Urologic Association Advocacy Conference 2005- 2006

AUA Young Leadership Executive Training Course 2006-2010

New York Academy of Medicine Urology Section Executive Committee 2006-2011

American Urologic Association Leadership Course 2005-2006 Vice Chairman American Joint Committee on Cancer Staging 2009 7th TNM Urologic Cancer Task Force 2006-2009.

American Board of Urology Exam Committee 2008-2012 NIH NIDDK K-23 grant review section 2010

Bladder Cancer Advisory Network Scientific Advisroy Board 2010-

AUA New York Section Scientific Committee Chair 2010 Society of Urologic Oncology Knowledge AssessmentTest (OKAT) Exam committee 2012-

American Board of Urology Oral Examination Committee 2013- Vice Chairman American Joint Committee on Cancer Staging 2013 8th edition TNM Urologic Cancer Task Force

Co-Chair 2016 American Urologic Association Non-Muscle Invasive Bladder Cancer Guidelines Committee

Selected visiting professorships and invited lectures:


2006 Hackensack University Medical Center Grand Rounds 2006 Northeast Section of the AUA Annual Meeting

2007 Beth Israel Department of Urology Grand Rounds 2007 Long Island Jewish Hospital Grand Rounds

2008 Irish Urologic Assocation Annual Meeting Cork City Ireland 2008 Society of Urologic Oncology Annual Meeting

2008 Henry Ford Hosptial Grand Rounds

2008 Wayne State University Karmonos Cancer Center 2008 Maimonides Medical Center Urology Grand Rounds 2009 University of San Juan Department of Urology

2009 Morristown Hospital Annual Prostate Cancer Lecture 2010 The Valley Hopsital Annual Prostate Cancer Lecture 2010 New York State Society of Oncology and Hematology 2010 Vanderbilt University Medical Center Visiting Professor 2010 Society of Urologic Oncology NCI Annual Meeting 2011 National Kidney Foundation Annual Meeting

2011 New Jersey Association of Oncology Annual Meeting 2011 Lahey Clinic Visiting Professor of in Urology

2012 Winthrop University Hospital Grand Rounds

2012 Cornell University Department of Urology Grand Rounds 2012 Society of Urologic Oncology NCI Annual Meeting

2013 Lahey Clinic Department of Urology Visiting Professor

2013 John Mordente Visiting Lecture in Urology Winthrop Hospital NY 2014 UCLA State of the Art Urology Symposium

2015 Southeastern Section AUA Visiting Professor

2015 Medical University of South Carolina Dept of Urology Visiting Professor 2015 Boston Universtiy Department of Urology Robert Krane Visiting Professor


Publications


  1. Goluboff ET, McKiernan JM, Todd G, Nowygrod R, Smith D, Olsson CA. Reconstruction of urinary and gastrointestinal tracts in total pelvic exenteration: experience at Columbia-Presbyterian Medical Center. Urology; 1994; 44; 666-670.


  2. McKiernan JM, Kaplan SA, Te AE, Santarosa RP, Sawczuck IS. Transurethral electrovaporization of bladder cancer. Urology; 1996; 48; 201-210.


  3. McKiernan JM, Katz AE, and Goluboff ET. A long forgotten ureteral stent.

    Urology; 1997; 49; 622.


  4. McKiernan JM, Lowe FC. Review of side effects of terazosin in the treatment of benign prostatic hyperplasia Southern Med Journal; 1997; 90; 509-513.


  5. McKiernan JM, Sawczuk IS. Transurethral electropvaporization of bladder tumors.

    Current Surgical Techniques in Urology; 1997. .

  6. Goluboff ET, McKiernan JM, and Sawczuk IS. Autologous T-cell therapy for metastatic renal cell carcinoma. Today’s Therapeutic Trends June; 1997.


  7. McKiernan JM, Buttyan R, Bander NH, Stifelman MD, Katz AE, Chen MW, Olsson CA, Sawczuk IS. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Research; 1997; 57; 2362-2365.


  8. Cooper KL, McKiernan JM, and Kaplan SA. Alpha Adrenoreceptor Antagonists in the Treatment of Benign Prostatic Hyperplasia. Drugs; 1999; 57; 9-17.


  9. McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase- polymerase chain reaction assay for MN/CA9. Cancer; 1999; 86; 492-497.


  10. McKiernan JM, Goluboff ET, Liberson GL, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. Journal of Urology; 1999; 162; 361-363.


  11. de la Taille A, Katz A, Cao Y, McKiernan J, Buttyan R, Burchardt M, Burchardt T, Hayek O, Olsson CA, Chopin DK, Sawczuk IS. Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients. Urology; 2000; 56; 393- 398.


  12. de la Taille A, Buttyan R, Katz AE, McKiernan J, Burchardt M, Burchardt T, Chopin DK, Sawczuk IS. Biomarkers of renal cell carcinoma. Past and future considerations. Urologic Oncology; 2000; 5:139-148.


  13. de la Taille A, Cao Y, Sawczuk IS, Nozemu T, d'Agati V, McKiernan JM, Bagiella E, Buttyan R, Burchardt M, Olsson CA, Bander N, Katz AE. Detection of prostate- specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion. Cancer Detect Prevention; 2000; 24; 579- 588.


  14. McKiernan J, Simmons R, Russo P. Renal cortical tumors: When is kidney-sparing surgery the standard of care? Contemporary Urology; 2002; 4; 48-62.


  1. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology; 2002; 59; 816-820.


  2. Gilbert SM, Benson MC, McKiernan JM. Linkage Disequilibrium Between the Androgen Receptor Gene CAG and GGC Repeats in the African-American Population. Current Urologic Reports; 2002; 3;189-193.


  3. McKiernan JM, Katz J, Teschendorff B, Herr HW, Russo P. Financial outcomes of partial and radical nephrectomy as treatment of renal tumors less than 4cm. Urologic

    Oncology; 2002; 7; 4-6.


  4. Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, Bosl GJ, Chaganti RS and Murty VVV. Characteristic Promoter Hypermethylation Signatures in Male Germ Cell Tumors. Molecular Cancer; 2002; 1; 8-12.


  5. McKiernan JM, Yossepowitch O, Kattan MW, Simmons R, Motzer R,Reuter Russo

    P. Partial Nephrectomy for Renal Cortical Tumors: Pathologic Findings and Impact on Outcome. Urology; 2002, 60; 1003-1009.


  6. Gilbert SM, Olsson CA, Benson MC, and McKiernan JM The role of intravenous zoledronic acid in the management of high-risk prostate cancer.. Current Opinions in Urology; 2003; 5; 239-244.


  7. Anastiadis AG, Benson MC, Rosenwasser MP, Salomon L, el-rashidy H, Ghafar M, McKiernan JM, Burchardt M, Shabsigh R. Cavernous nerve graft reconstruction durinng radical prostatectomy or radical cystectomy: safe and technically feasible. Prostate Cancer and Prostatic Disease; 2003; 6; 56-60.


  8. Fynn-Thompson N, McKiernan JM, Fay A. Transitional Cell Carcinoma of the Urinary Bladder Metastatic to the Orbit. Ophthalmologic Plastic Reconstructive Surgery; 2003; 19;165-167.


  1. Gilbert SM, Russo P, Benson MC, Olsson CA, and McKiernan JM. The evolving role of partial nephrectomy in the management of renal cell carcinoma. Current Oncology Reports; 2003; 5; 239-244.


  2. Sheinfeld J, Motzer RJ, Rabbani F, McKiernan J, Bajorin D, and Bosl GJ. Incidence and clinical outcome of patients with teratoma in retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. Journal of Urol; 2003; 170; 1159-1162.


  3. McKiernan JM, Motzer RJ, Bajorin DF, Bacik J, Bosl GJ, and Sheinfeld J Re-operative retroperitoneal surgery for non-seminomatous germ cell tumor:

    Clinical presentation, patterns of recurrence, and outcome. Urology; 2003; 62; 732-736.


  4. Jewett MA, Grabowski A, McKiernan JM. Management of recurrence and follow- up strategies for patients with nonseminoma testis cancer..Urologic Clinics of North America; 2003; 30; 819-30.


  5. Salomon L, Anastasiadis AG, Johnson CW, McKiernan JM, Goluboff ET, Abbou CC, Olsson CA, Benson MC. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology; 2003; 62; 304-309.


  6. Moschella F, Catanzaro RP, Bisikirska B, Sawczuk IS, Papadapoulos KP, Ferrante AW Jr, McKiernan JM, Hesdorffer CS, Harris PE, Maffei A.Shifting gene expression

    profiles during ex vivo culture of renal tumor cells: implications for cancer immunotherapy. Oncology Research; 2003; 14; 133-145.


  7. Goetzl MA, Desai M, Mansukhani M, Goluboff ET, Katz AE, Sawczuk IS, Benson MC, Olsson CA, McKiernan JM. Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult. Urology; 2004; 63; :41-45.


  8. Goetzl MA, Goluboff ET, Murphy AM, Katz AE, Mansukhani M, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long term survival. Urologic Oncology; 2004; 22: 182-187.


  9. Johnson CW, McKiernan JM, Anastasiadis AG, Salomon L, Eaton S, Goluboff ET, Olsson CA, Benson MC. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. Urologic Oncology; 2004; 107-111.


  10. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski D, Assaad A, Mansukhani M, Reuter VE, Bosl GJ, Chaganti RS, Murty VV. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Molecular Cancer; 2004; 3:16-22.


  11. McKiernan J, Benson MC. Predicting the clinical course of prostate cancer. Journal of Clinical Investigation; 2004; 113; 806-808.


  12. Shah JB, McKiernan JM. Novel therapeutics in the treatment of bladder cancer.

    Current Opinions in Urology; 2004; 14; 287-293.


  13. Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. Journal of Urology; 2004; 172; 1822-1824.


  14. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology; 2004; 67; 390-396.


  15. Murphy AM, Gilbert SM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). British Journal of Urology International; 2005; 95; 27-30.


  16. Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Current Opinions in Urology; 2005; 23-27.


  17. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. Journal of Urology; 2005; 173; 48-51.

  1. Shah JB, Reese AC, McKiernan JM, Benson MC. PSA updated: still relevant in the new millennium: European Urology; 2005; 47; 427-432.


  2. Katz MH, McKiernan JM. Management of residual germ cell tumor masses outside the retroperitoneum after chemotherapy. Urologic Oncology; Seminars and original investigations.2005; 23; 431-439.


  3. Mitchell RE, Katz MH, McKiernan JM, Benson MC. The evaluation and staging of clinically localized prostate cancer. Nature Clinical Practice Urology; 2005; 2; 356-357.


  4. Mitchell RE, Shah JB, Olsson CA, Benson MC, MCKiernan JM. Does year of radical prostatectomy independently predict outcome in prostate cancer?

Urology; 2006; 67;368-372.


45 . Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology; 2006; 67; 260-264.


  1. Saad F, McKiernan JM, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urologic Oncology; 2006; 24; 4-12.


  2. Mitchell RE, Desai M, Shah JB, Olsson CA, Benson MC, McKiernan JM. Preoperative serum PSA remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. J Urol, 2006; 175; 1663-7.


  3. Gilbert SM, Olsson CA, Benson MC, Sawczuk IS, McKiernan JM. Serum MN/CA 9 levels are predictive of outcome in patients with renal cortical tumors. Urology, 2006; 67:942-945.


  4. Gilbert SM, McKiernan JM. The role of bisphosphonates in preventing complications of hormonal therapy. Urol Clin North Am 2006; 33: 191-199.


  5. Shah JB, Badalato GM, McKiernan JM New treatments for superficial bladder cancer. Curr Oncol Rep, 2006; 8: 201-205.


  6. McKiernan JM, Murphy AM, Goetzl M, Masson P, Desai M, Olsson CA, Petrylak DP, Benson MC. Phase I trial of intravesical Docetaxel in the treatment of superficial bladder cancer resistant to standard intravesical therapy. J Clin Oncol. 2006; 24:3075-80.


  7. Gilbert SM, Murphy AM, Katz AE, GOluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology. 2006;68:287- 91.


  8. Memeo L, Jhang J, Assaad AM, McKiernan JM, Murty VV, Hibshoosh H, Tong GX, Mansukhani MM. Immunohistochemical analysis for cytokeratin 7, KIT, and

    PAX2,: value in the differential diagnosis of chromphobe cell carcinoma. Am J Clin Pathol. 2007: 127: 225-229.


  9. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.

    J Support Oncol. 2006;4:341-7.


  10. Pierorazio PM, Murphy AM, Benson MC, McKiernan JM. Gender discrepancies in the diagnosis of renal cortical tumors. World J Urol 2006.


  11. Collins S, McKiernan JM, Landman J: Update on the epidemiology and biology of renal cortical neoplasms. J Endourol. 2006;20:975-85.


  12. Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol. 2006;1:571-6.


  13. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006; 4: 341-347.


  14. Pierorazio PM, Lambert SM, Matsukhani M, Sprenkle PC, McCann TR, Katz AE, Olsson CA, Benson MC, McKiernan JM. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU Int 2007.


  15. Mitchell RE, Shah JB, Desai M, Mansukhani MM, Olsson CA, Benson MC, McKiernan JM. Changes in Prognostic Significance and Predictive Accuracy of Gleason Grading System Throughout PSA Era: Impact of Grade Migration in Prostate Cancer. Urology 2007; 70:706-710.


  16. Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology. 2007;69: 1054-8.


  17. Katz MH, McKiernan JM. High-risk, clinically localized prostate cancer: is monotherapy adequate? Rev Urol. 2007;9: S19-27.


  18. Lambert EH, Pierorazio PM, Poon S, Olsson CA, Benson MC, McKiernan JM.

    The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33-6.


  19. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007; 100:755-759.


  20. Pierorazio PM, Kinnaman MD, Wosnitzer MS, Benson MC, McKiernan JM, Goluboff ET. Prostate volume and pathologic prostate cancer outcomes after radical prostatectomy. Urology. 2007; 70:696-701.


  21. Pierorazio PM, Spencer BA, McCann TR, McKiernan JM, Benson MC. Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy. Urology 2007; 70: 717-22.


  22. Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM. Local control and long-term disease-free survival for stage D1 (T2- T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.: Urology 2007; 70:723-7.


  23. Shah JB, McKiernan JM, Elkin CP, Carroll PR, Meng MV; CaPSURE investigators. Prostate biopsy patterns in the CaPSURE database:evolution with time and impact on outcome after prostatectomy. Journal of Urol 2008; 179: 136-140.


  24. Decastro JG, McKiernan JM. Epidemiology and staging of renal cell carcinoma.

    Urol Clin North Am. 2008; 35:581-92.


  25. Gonzalez JR, Consedine NS, McKiernan JM, Spencer BA. Barriers to the initiation and maintenance of prostate specific antigen screening in Black American and Afro-Caribbean men. Journal of Urol 2008; 180: 2403-8.


  26. Gonzalez JR, Laudano MA, McCann TR, McKiernan JM, Benson MC. A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies. World J Urol. 2008; 26: 475-80.


  27. Laudano MA, Klafter FE, Katz M, McCann TR, Desai M, Benson MC, McKiernan JM. Pathological tumour diameter predicts risk of conventional subtype in small renal cortical tumours. BJU Int. 2008 102: 1385-8.


  28. Mann MJ, DeCastro GJ, Desai M, Benson MC, McKiernan JM. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era. Urology. 2008;72:1203-7.

  29. Consedine N, Adjei B, Ramirez P, McKiernan JM. An object lesson: Source determines the relations that trait anxiety, prostate cancer worry, and screening fear hold with prostate screening frequency. Cancer Epidemiol Biomarkers Prev. 2008; 17:1631-9.


  30. Montamedina P, Korets R, Spencer BA, Benson MC, McKiernan JM. Body mass index trends and the role of obesity in predicting outcome following radical prostatectomy. Urology 2008; 72:1106-10.


  31. DeCastro GJ, McCann T, Benson MC, McKiernan JM. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy. Urology. 2008; 72: 1214-8.


  32. Lehman DS, Hruby GW, Phillips CK, McKiernan JM, Benson MC, Landman J.

    Laparoscopic renal cryoablation: efficacy and complications for larger renal masses. J Endourol. 2008; 22: 1123-7.


  33. Laudano MA, Lambert SM, Masson P, McCann TR, Desai M, Benson MC, McKiernan JM. How often do available preoperative risk factors accurately predict the risk assessed after surgery for localized prostate cancer? BJU Int 2009; 103: 317-20.


  34. Pierorazio P, Desai M, McCann T, Benson M, McKiernan JM. The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome. BJU Int. 2009; 103: 38-42.


  35. Poon SA, Gonzalez JR, Benson MC, McKiernan JM. Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma. BJU Int. 2009; 103: 1622-25.


  36. Gonzalez JR, Consedine NS, McKiernan JM, Spencer BA.Barriers to the initiation and maintenance of prostate specific antigen screening in Black American and Afro-Caribbean men. J Urol. 2008;180:2403-8.


  37. Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 2009; 27: 331-5.


83. Consedine NS, Adjei BA, Horton D, Joe AK, Borrell LN, Ramirez PM, Unger T, McKiernan JM, Jacobson JS, Magai C, Neugut AL. Fear and loathing in the Caribbean: three studies of fear and cancer screening in Brooklyn’s immigrant Caribbean subpopulations. Infect Agent Cancer 2009; 10: S14.

  1. Murphy AM, Buck AM, Benson MC, McKiernan JM. Increasing detection rate of benign renal tumors: Evaluation of factors predicting for benign tumor histologic features during past two decades. Urology 73: 1293-7.


  2. Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, Benson MC, Stone BA, Katz AE. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 2009: 7: 43-51.


  3. Barlow L, McKiernan JM, Sawczuk I, Benson MA. single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle- invasive bladder cancer refractory to bacille Calmette-Guérin therapy. British J Urol 2009.


  4. Lee DJ, Rothberg MB, McKiernan JM, Benson MC, Badani KK. Robot-assisted radical cystoprostatectomy in complex surgical patients: single institution report. Can J Urol. 2009;16:4664-9.


  5. Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM, Badani KK. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int. 2009.


  6. Barlow LJ, Poon SA, McKiernan JM. The Case of a Poorly Differentiated Gastric Adenocarcinoma Disguised as a Testicular Germ Cell Tumor in a 34-year-old Male. Urology. 2009;74:722-5.


  7. Murphy AM, McKiernan JM. Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor. World J Urol. 2009;27:501-6.


  8. Laudano MA, Badani KK, McCann TR, Mann MJ, Ritch C, Desai M, Benson MC, McKiernan JM. Significant change in predicted risk of biochemical recurrence after radical prostatectomy more common in black than in white men. Urology. 2009;74:660-4.


  9. Dahm P, Rosser CJ, McKiernan JM. Quality of care for testis cancer. Urol Oncol 2009; 27;448-53.


  10. Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the prostate gland.Arch Pathol Lab Med. 2009;133:1568-76.

  11. Barlow LJ, Badalato GM, Bashir T, Benson MC, McKiernan JM. The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy. BJU Int. 2009 Oct 26.


  12. Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010 Jan;75(1):134-7.


  13. Barlow LJ, Mann MJ, Badani KK, Benson MC, McKiernan JM. Has the advent of minimally invasive surgery altered the risk profile of patients undergoing prostatectomy? Urology. 2010 Feb;75(2):427-30.

  14. Woldu SL, Barlow LJ, Patel T, Hruby GW, Benson MC, McKiernan JM. Single Institutional Experience with Nephron-sparing Surgery for Pathologic Stage T3bNxM0 Renal Cell Carcinoma Confined to the Renal Vein. Urology. 2010 Feb 15.

  15. Barlow LJ, Seager CM, Benson MC, McKiernan JM. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. Urol Oncol. 2010 Jan-Feb;28(1):108-11.


  16. Rosales JC, Haramis G, Moreno J, Badani K, Benson MC, McKiernan J, Casazza C, Landman J. Active surveillance for renal cortical neoplasms. Journal of Urol. 2010 May;183(5):1698-702.


  17. Patel T, Pitman M, McKiernan JM. Bladder cancer: a review of clinical management and prognostic factors. Minerva Urol Nefrol. 2010 Dec; 62(4):377-86.


  18. Lee DJ, Ritch C. Desai M, Benson MC, McKiernan JM. The interaction of body mass index and race in predicting biochemical failure after radical prostatectomy. BJU Int. 2010 Oct 13.


  19. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin. Urology. 2010 Jun 3.

  20. Lee DJ, Hruby G, Benson MC, McKiernan JM. Renal function and oncologic outcomes in nephron sparing surgery for renal masses in solitary kidneys. World J Urol. 2010 Jul 11.


  21. Mues AC, Haramis G, Badani K, Gupta M, Benson MC, McKiernan JM, Landman J. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology. 2010 Sep;76(3):620-3.


  22. Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol. 2010 Nov;7(11):610-7.


  23. Patel T, Kirby W, Hruby G, Benson MC, McKiernan JM, Badani K. Heparin prophylaxis and the risk of venous thromboembolism after robotic-assisted laparoscopic prostatectomy. BJU Int. 2011 Jan 13.


  24. Korets R, Motamedinia P, Yeshchina O, Desai M, McKiernan JM. Accuracy of the Kattan nomogram across prostate cancer risk-groups.BJU Int. 2010 Nov.


  25. Badalato G, Patel T, Hruby G, McKiernan J. Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer? BJU Int. 2010 Dec 22.


  26. Mues AC, Palacios JM, Haramis G, Casazza C, Badani K, Gupta M, McKiernan J, Benson MC, Landman J. Contemporary experience in the management of angiomyolipoma. J Endourol. 2010 Nov;(11):1883-6.


  27. Haramis G, Mues AC, Rosales JC, Okhunov Z, Lanzac AP, Badani K, Gupta M, Benson MC, McKiernan J, Landman J. Natural History of Renal Cortical Neoplasms During Active Surveillance With Follow-up Longer Than 5 Years. Urology. 2010 Dec 15.


  28. Wosnitzer M, Polland A, Hai Q, Hruby G, McKiernan J. Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies. BJU Int. 2010 Dec 16.


  29. McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound (nab-)paclitaxel (Abraxane® ABI-007) in the treatment of BCG refractory non-muscle-invasive bladder cancer. J ournal of Urol. 2011 Aug;186(2):448-51


  30. Sadeghi N, Badalato GM, Kates M, McKiernan JM. Management of residual non-retroperitoneal disease following chemotherapy for germ cell tumor. Urol Oncol. 2011 Nov-Dec;29(6):837-41.

  31. Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int. 2011 Mar 31.


  32. Sadeghi N, Grann V, McKiernan JM. Does Absolute Neutrophil Count Predict High Tumor Grade in African-American Men with Prostate Cancer? The Prostate 2012 Mar;72(4):386-91.


  33. Badalato GM, Hruby G, Razmjoo M, McKiernan JM. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? Can J Urol. 2011:5890-5.

  34. Ritch CR, Kearns JT, Mues AC, Hruby GW, Benson MC, McKiernan JM, Landman J.Comparison of distal ureteral management strategies during laparoscopic nephroureterectomy. J Endourol. 2011 Jul;25(7):1149-54.


  35. Wosnitzer MS, Hruby GW, Murphy AM, Barlow LJ, Cordon-Cardo C, Mansukhani M, Petrylak DP, Benson MC, McKiernan JM. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer. Cancer; 2012 Jan: 118(2):358-64.


  36. Kates M, Badalato GM, McKiernan JM. Renal functional outcomes after surgery for renal cortical tumors. Curr Opin Urol. 2011 Sep:351-5.


  37. Truesdale MD, Polland AR, Graversen JA, Sartori S, Hruby GW, Landman J, McKiernan JM, Benson MC, Badani KK. Impact of HMG-CoA reductase inhibitor (statin) use on blood loss during robot-assisted and open radical prostatectomy. J Endourol. 2011 Sep;25(9):1427-33.

  38. Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM, Shen J. DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer. DNA Cell Biol. 2012 Feb;31(2):187-92.

  39. Kates M, Badalato G, Pitman M, McKiernan J. Persistent overuse of radical nephrectomy in the elderly. Urology. 2011 Sep;78(3):555-9.

  40. Donin NM, Suh LK, Barlow L, Hruby GW, Newhouse J, McKiernan J Tumour diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma. BJU Int. 2012 Feb;109(3):379-83.

  41. Graversen JA, Suh LK, Mues AC, Korets R, Donovan MJ, Khan FM, Liu Q, Landman J, Gupta M, McKiernan JM, Badani KK. Independent Diagnostic and Post- treatment Prognostic Models for Prostate Cancer Demonstrate Significant Correlation with Disease Progression End Points. J Endourol. 2012 May;26(5):451-6.


  42. Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylak DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive

    bladder cancer receiving adjuvant intravesical taxane therapy. Journal of Urol. 2011 Nov;186(5):2094-100.


  43. Kates M, Korets R, Sadeghi N, Pierorazio PM, McKiernan JM. Predictors of locally advanced and metastatic disease in patients with small renal masses. BJU Int. 2012 May;109(10):1463-7.


  44. Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int. 2012 May;109(10):1457-62.


  45. Graversen JA, Suh LK, Mues AC, Korets R, Donovan MJ, Khan FM, Liu Q, Landman J, Gupta M, McKiernan JM, Badani KK. Independent diagnostic and post- treatment prognostic models for prostate cancer demonstrate significant correlation with disease progression end points. J Endourol. 2012 May;26(5):451-6.


  46. Badalato GM, Hruby G, Razmjoo M, McKiernan JM. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? Can J Urol. 2011 Oct;18(5):5890-5.


  47. Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Int. 2012 Jul;110(2):211-6.


  48. Silva MV, Motamedinia P, Badalato GM, Hruby G, McKiernan JM. Diagnostic radiation exposure risk in a contemporary cohort of male patients with germ cell tumor. Journal of Urol. 2012 Feb;187(2):482-6.


  49. Yeshchina O, Badalato GM, Wosnitzer MS, Hruby G, RoyChoudhury A, Benson MC, Petrylak DP, McKiernan JM. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology. 2012 Feb;79(2):384- 90.


  50. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012 Sep 15;72(13):1469-77.


  51. Godfrey MS, Badalato GM, Hruby GW, Razmjoo M, McKiernan JM. Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion. BJU Int. 2012 Sep;110(6):798-803.


  52. Badalato GM, Gaya JM, Hruby G, Patel T, Kates M, Sadeghi N, Benson MC, McKiernan JM. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int. 2012 Apr 4.

  53. Kates M, Badalato GM, Gupta M, McKiernan JM.

    Secondary bladder cancer after upper tract urothelial carcinoma in the US population.

    BJU Int. 2012 Nov:1325-9.


  54. Kates M, Whalen MJ, Badalato GM, McKiernan JM.

    The effect of race and gender on the surgical management of the small renal mass.

    Urol Oncol. 2012 Jun 9.


  55. Shapiro EY, Lipsky MJ, Cha DY, McKiernan JM, Benson MC, Gupta M. Outcomes of Intrarenal Bacillus Calmette-Guérin/Interferon-α2B for Biopsy-Proven Upper-Tract Carcinoma in Situ. J Endourol. 2012 Oct 9.


  56. Sadeghi N, Badalato GM, Hruby G, Kates M, McKiernan JM. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. Can J Urol. 2012 Oct;19(5):6443-9.


140. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM.

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec;188(6):2391- 7.


141. Richard JL, Motamedinia P, McKiernan JM, DeCastro GJ, Benson MC. Routine transition zone biopsy during active surveillance for prostate cancer rarely provides unique evidence of disease progression. J Urol. 2012 Dec;188(6):2177-80.


142. Fast AM, Deibert CM, Boyer C, Hruby GW, McKiernan JM.

Partial nephrectomy online: a preliminary evaluation of the quality of health information on the Internet. BJU Int. 2012 De:765-9.


  1. Ritch CR, Morrison BF, Hruby G, Coard KC, Mayhew R, Aiken W, Benson MC, McKiernan JM. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian- American men: an international comparison. BJU Int. 2013 Apr:111: 186-90.


  2. Pitman M, Korets R, Kates M, Hruby GW, McKiernan JM. Socioeconomic and clinical factors influence the interval between positive prostate biopsy and radical prostatectomy. Urology. 2012 Nov;80(5):1027-32.


  3. Motamedinia P, RiChard JL, McKiernan JM, DeCastro GJ, Benson MC Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance. Urology. 2012 Nov;80:1070-4.

  4. Barlow L, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. Journal of Urol. 2013 Mar;189:834-9.

  5. Hruby GW, McKiernan J, Bakken S, Weng C. A centralized research data repository enhances retrospective outcomes research capacity: a case report.

    J Am Med Inform Assoc. 2013 May:(3):563-7.


  6. Joice GA, Deibert CM, Kates M, Spencer BA, McKiernan JM. .“Never events": Centers for Medicare and Medicaid Services complications after radical cystectomy. Urology. 2013 Mar;81:527-32.


  7. Lipsky MJ, Badalato GM, Motamedinia P, Hruby GW, McKiernan JM. The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette- Guérin therapy for non-muscle-invasive bladder cancer. Urology. 2013 Jun;81:1273-8.


  8. Lipsky MJ, Shapiro EY, Hruby GW, McKiernan JM.

    Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma. Urology. 2013 Jun;81:1190-5.


  9. McKiernan J, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Journal of Urol. 2013 Aug;190:386-8.


  10. Delto JC, Kobayashi T, Benson M, McKiernan J, Abate-Shen C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget. 2013 Feb;4:269-76.


  11. Lin J, Whalen M, Holder D, Hruby G, Decastro GJ, McKiernan J. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology. Can J Urol. 2013 Apr;20: 6690-5.


  12. Lipsky MJ, Shapiro EY, Hruby GW, McKiernan JM. Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma. Urology. 2013 Jun;81:1190-5.

  13. Delto JC, Kobayashi T, Benson M, McKiernan J, Abate-Shen C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget. 2013 Feb;4(2):269-76.


    image

    image

    image

  14. McKiernan J, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol. 2013 Aug;190(2):386-8.


  15. Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. Eur Urol. 2014 Sep;66(3):577-83.

  16. Shapiro EY, Scarberry K, Patel T, Bergman A, Ahn J, Sahi N, Roychoudhury A, Deutsch I, McKiernan JM, Benson MC, Badani KK. Comparison of robotic assisted and open retropubic radical prostatectomy for risk of biochemical progression in men with positive surgical margins. J Endourol. 2014 Feb;28(2):208-13.


  17. McKiernan JM, Holder DA, Ghandour R, Ahn JJ, Badalato G, Roychoudry A, Benson MC. Phase II trial of nanoparticle encapsulated paclitaxel in the treatment of non muscle invasive urothelial bladder cancer recurring after BCG. J Urol 2014 Dec;192(6):1633-8.


  18. Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, Bivalacqua TJ. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. Urol Oncol. 2014 Jan;32(1):53.


  19. Lin J, Deibert CM, Holder D, Benson MC, McKiernan JM.

    The role of pelvic lymphadenectomy in non-muscle invasive bladder cancer. Can J Urol. 2014 Feb;21(1):7108-13.


  20. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

    Curr Urol Rep. 2014 May;15(5):404.


  21. Ahn JJ, Ghandour RA, McKiernan JM. New agents for bacillus Calmette- Guérin-refractory nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep;24(5):540-5.


  22. Stevenson SM, Danzig MR, Ghandour RA, Deibert CM, Decastro GJ, Benson MC, McKiernan JM. Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Urol Oncol. 2014 Nov;32(8):1172-7.


  23. Woldu SL, Weinberg AC, RoyChoudhury A, Chase H, Kalloo SD, McKiernan JM, DeCastro GJ. Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int Urol Nephrol. 2014 Nov;46(11):2127-32.


  24. Danzig MR, McKiernan JM. Overtreatment of men with early-stage prostate cancer and limited life expectancy. Cancer. 2014 Dec 1;120(23):3592-4.


  25. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez- Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P,

    Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb;193(2):436-42.


  26. Schubert T, Danzig MR, Kotamarti S, Ghandour RA, Lascano D, Dubow BP, Decastro GJ, Benson MC, McKiernan JM. Mixed low- and high-grade non-muscle- invasive bladder cancer: a histological subtype with favorable outcome.

    World J Urol. 2015 Jun;33(6):847-52.


  27. Danzig MR, Weinberg AC, Ghandour RA, Kotamarti S, McKiernan JM, Badani KK. The association between socioeconomic status, renal cancer presentation, and survival in the United States: a survival, epidemiology, and end results analysis. Urology. 2014 Sep;84(3):583-9.


  28. Gaya JM, Matulay J, Badalato GM, Holder DD, Hruby G, McKiernan J.

    The role of preoperative prostatic urethral biopsy in clinical decision-making at the time of radical cystectomy. Can J Urol. 2014 Apr;21(2):7228-33.


  29. Meyer A, Ghandour R, Bergman A, Castaneda C, Wosnitzer M, Hruby G, Benson M, McKiernan J. The natural history of clinical complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.

    J Urol. 2014 Sep;192(3):696-701.


  30. Pagano MJ, Badalato G, McKiernan JM. Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited. Curr Urol Rep. 2014 Nov;15(11):450.


  31. Gaya JM, Matulay J, Badalato GM, Holder DD, Hruby G, McKiernan J.

    The role of preoperative prostatic urethral biopsy in clinical decision-making at the time of radical cystectomy. Can J Urol. 2014 Apr;21(2):7228-33.


  32. Woldu SL, Weinberg AC, Korets R, Ghandour R, Danzig MR, RoyChoudhury A, Kalloo SD, Benson MC, DeCastro GJ, McKiernan JM. Who really benefits from nephron-sparing surgery? Urology. 2014 Oct;84(4):860-7.


  33. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, Badani KK, McKiernan JM, Benson MC, Hibshoosh H, Shen MM. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol. 2014 Oct;16(10):951-61.


  34. Whalen MJ, RIChard JL, Ghandour R, Lipsky M, Piecuch M, Benson MC, Nieder AM, Decastro GJD, McKiernan JM. Lessons Learned from Routine

    Intraoperative Ureteral Margin Frozen Sections during Radical Cystectomy. Urology Practice 2014; 2; 90-95.


  35. Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges.

    Nat Rev Cancer. 2015 Jan;15(1):42-54.


  36. Perez TY, Danzig MR, Ghandour RA, Badani KK, Benson MC, McKiernan JM. Impact of the 2012 United States Preventive Services Task Force statement on prostate- specific antigen screening: analysis of urologic and primary care practices. Urology. 2015 Jan;85(1):85-9.


  37. Danzig MR, Kotamarti S, Ghandour RA, Rothberg MB, Dubow BP, Benson MC, Badani KK, McKiernan JM. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):63-8.


  38. Castañeda CV, Danzig MR, Finkelstein JB, RoyChoudhury A, Wagner AA, Chang P, Pierorazio PM, Allaf ME, McKiernan JM. The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. Urol Oncol. 2015 Apr;33(4):166.e17-20.


  39. Pak JS, Shapiro E, Margolskee EM, McKiernan JM.

    Hypermetabolic residual retroperitoneal mass after chemotherapy for primary seminoma. Urology. 2015 May;85(5):987-90.


  40. Kotamarti S, Rothberg MB, Danzig MR, Levinson J, Saad S, Korets R, McKiernan JM, Badani KK. Increasing volume of non-neoplastic parenchyma in partial nephrectomy specimens is associated with chronic kidney disease upstaging. Clin Genitourin Cancer. 2015 Jun;13(3):239-43.


  41. Berg WT, Danzig MR, Pak JS, Korets R, RoyChoudhury A, Hruby G, Benson MC, McKiernan JM, Badani KK. Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes. Prostate. 2015 Jul 1;75(10):1085-91.


  42. Ghandour RA, Danzig MR, McKiernan JM. Renal cell carcinoma: risks and benefits of nephron-sparing surgery for T1 tumors. Adv Chronic Kidney Dis. 2015 Jul;22(4):258-65.


  43. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez- Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional

    Analysis. J Urol. 2015 Aug;194(2):304-8.


  44. Woldu SL, Thoreson GR, Okhunov Z, Ghandour R, Rothberg MB, RoyChoudhury A, Kim HH, Bozoghlanian M, Newhouse JH, Helmy MA, Badani KK, Landman J, Cadeddu JA, McKiernan JM. Comparison of Renal Parenchymal Volume Preservation Between Partial Nephrectomy, Cryoablation, and Radiofrequency Ablation Using 3D Volume Measurements. J Endourol. 2015 Aug;29(8):948-55.


  45. Deibert CM, Kates M, McKiernan JM, Spencer BA.

    National estimated costs of never events following radical prostatectomy. Urol Oncol. 2015 Sep;33(9):385.e1-6.


  46. Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015 Sep;68(3):408-15.


  47. Lascano D, Finkelstein JB, Barlow LJ, Kabat D, RoyChoudhury A, Caso JR, DeCastro GJ, Gold W, McKiernan JM. The Correlation of Media Ranking's "Best" Hospitals and Surgical Outcomes Following Radical Cystectomy for Urothelial Cancer. Urology. 2015 Sep 22: S0090-4295(15)00879-1.


  48. Meyer A, Woldu SL, Weinberg AC, Thoreson GR, Pierorazio P, Matulay JT, Benson MC, DeCastro GJ, McKiernan JM. Predicting Renal Parenchymal Loss after Nephron Sparing Surgery. J Urol. 2015 Sep;194(3):658-63.


  49. Lascano D, Pak JS, Kates M, Finkelstein JB, Silva M, Hagen E, RoyChoudhury A, Bivalacqua TJ, DeCastro GJ, Benson MC, McKiernan JM.

    Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools.

    Urol Oncol. 2015 Oct;33(10):426.


  50. Pak JS, Lascano D, Kabat DH, Finkelstein JB, RoyChoudhury A, DeCastro GJ, Gold W, McKiernan JM. Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation.

    Urol Oncol. 2015 Oct;33(10):426.e13-9.


  51. Danzig MR, Ghandour RA, Chang P, Wagner AA, Pierorazio PM, Allaf ME, McKiernan JM. Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry.

    J Urol. 2015 Oct;194(4):903-9.


  52. Pagano MJ, Whalen MJ, Paulucci DJ, Reddy BN, Matulay JT, Rothberg M, Scarberry K, Patel T, Shapiro EY, RoyChoudhury A, McKiernan J, Benson MC, Badani KK. Predictors of biochemical recurrence in pT3b prostate cancer after radical

    prostatectomy without adjuvant radiotherapy. Prostate. 2015 Oct 20.


  53. Danzig MR, Chang P, Wagner AA, Allaf ME, McKiernan JM, Pierorazio PM. Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. Curr Urol Rep. 2016 Jan;17(1):4.


Book Chapters:


  1. Sheinfeld J, McKiernan JM, Bosl GJ. Surgery of Testicular Neoplasms.

    Campbell’s Urology, 8th Ed., Vol .4, 2002.


  2. Benson MC, McKiernan JM, Olsson CA. Continent Cutaneous Urinary Diversion. Campbell’s Urology 9th Ed., Vol 4 2006.


  3. Katz M, McKiernan JM. Management of Non-retroperitoneal residual postchemotherapy masses in germ cell tumor. Urol Clin of North Am 2006.


  4. Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am. 2008 (4):581-92..


  5. McKiernan JM, Pierorazio PM: Beyond BCG: Taxanes. Bladder Cancer 2009.


  6. Benson MC, McKiernan JM. Continent Cutaneous Urinary Diversion.

    Campbell’s Urology 10th Ed., Vol 4 2010.

  7. American Joint Committee on CancerTNM Staging Manual, Genitourinary System. 7th edition October 2009.

8. Woldu SL, McKiernan JM.

Reoperative Retroperitoneal Surgery: Etiology and Clinical Outcome. Urol Clin North Am. 2015 Aug;42(3):381-92.


Abstracts and oral presentations not listed


Patents: Enhanced reverse transcription polymerase chain assay to detect MN/CA9 in patients with renal cell carcinoma.

7/11/00 US patent # 6,087,098.